Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to achieve statistical significance. As a result, Fulcrum plans to suspend the losmapimod program in FSHD.

Key results include:

• Losmapimod group: 0.013 improvement in RSA
• Placebo group: 0.010 improvement in RSA
• No significant differences in muscle fat infiltration, shoulder abductor strength, or patient-reported outcomes

Despite this setback, Fulcrum remains financially stable with $273.8 million in cash and equivalents as of June 30, 2024. The company will redirect its resources to advance pociredir for sickle cell disease and other early-stage programs.

Positive

• Fulcrum maintains a strong financial position with $273.8 million in cash and equivalents
• The company will redirect resources to advance pociredir for sickle cell disease treatment
• Safety and tolerability profile of losmapimod was consistent with previous studies

Negative

• Phase 3 REACH trial for losmapimod in FSHD failed to meet its primary endpoint
• Secondary endpoints did not achieve statistical significance
• Fulcrum plans to suspend the losmapimod program in FSHD
• The trial results did not replicate the positive outcomes observed in the Phase 2 ReDUX4 trial

Medical Research Analyst

The failure of losmapimod in the Phase 3 REACH trial for FSHD is a significant setback for Fulcrum Therapeutics. The drug did not show statistically significant improvements in the primary endpoint (RSA) or secondary endpoints compared to placebo. This outcome is particularly disappointing as it contradicts the promising results seen in the Phase 2 ReDUX4 trial.

The unexpected stability in the placebo group's functional status over 48 weeks is noteworthy, as it deviates from typical FSHD progression patterns. This raises questions about the trial design, patient selection, or potential placebo effect. The decision to suspend the losmapimod program in FSHD is a prudent move, given the clear lack of efficacy demonstrated in this large-scale study.

On a positive note, the consistent safety profile of losmapimod may still hold value for potential applications in other indications. The company's robust cash position of $273.8 million provides a substantial runway to pivot focus towards other promising candidates in their pipeline, particularly pociredir for sickle cell disease.

Financial Analyst

The failure of losmapimod in the Phase 3 REACH trial is likely to have a negative impact on Fulcrum Therapeutics' stock in the short term. Investors typically react strongly to late-stage clinical trial failures, especially for lead candidates. However, the company's strong cash position of $273.8 million as of June 30, 2024, provides a significant buffer, potentially mitigating some investor concerns.

The decision to suspend the losmapimod program will free up resources for other pipeline candidates, particularly pociredir for sickle cell disease. This strategic pivot could be viewed positively by long-term investors, as it allows the company to focus on potentially more promising assets. The sickle cell disease market represents a substantial opportunity, which could offset some of the disappointment from the FSHD program failure.

Investors will likely closely monitor the company's burn rate and progress in other programs to assess Fulcrum's long-term viability and growth potential. The company's ability to effectively allocate its resources and advance its remaining pipeline will be important for maintaining investor confidence.

― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―

― Fulcrum to suspend future losmapimod development ―

― Robust cash position enables Fulcrum to continue its mission to develop therapies addressing diseases of high unmet need including pociredir for the treatment of sickle cell disease (SCD) ―

CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance. The safety and tolerability profile of losmapimod was consistent with previously reported studies. The Company will complete a full evaluation of the data it received this week and plans to share the results at an upcoming medical meeting.

“We are deeply disappointed that the REACH trial did not replicate the clinical results observed in the Phase 2 ReDUX4 trial,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “In light of these results, we plan to suspend the losmapimod program in FSHD. We would like to thank the FSHD patients who participated in losmapimod clinical trials, their families, the investigators, the FSHD Society, and the broader FSHD community for their unwavering support for this program.”

Top-line REACH study results:

• Reachable Workspace (RWS): Participants receiving losmapimod demonstrated a 0.013 (±0.007) improvement in RSA at week 48 compared to placebo patients who showed a 0.010 (±0.007) improvement in RWS (p-value = 0.75).
• Muscle Fat Infiltration (MFI) as measured by Magnetic Resonance Imaging (MRI): Participants receiving losmapimod demonstrated an increase of 0.42% in MFI at week 48 compared to participants receiving placebo who showed an increase of 0.576% in MFI (p-value = 0.16).
• Shoulder Abductor Strength as measured by Hand-Held Dynamometry: Participants receiving losmapimod demonstrated a 9.63% improvement in abductor strength at week 48 compared to a 2.24% improvement in abductor strength seen in the placebo arm of the study (p-value = 0.51).
• Patient Reported Outcomes (PRO): Across the two PRO secondary endpoints in the REACH study, Patient Global Impression of Change (PGIC) and the Neuro QoL Upper Extremity, there were no statistically significant differences observed.
• Safety and Tolerability: The rate of treatment-related adverse events was similar in the two treatment arms, and there were no treatment-related serious adverse events in participants receiving losmapimod.
  

“These results in patients receiving losmapimod when compared to baseline were similar to those observed in our Phase 2 study,” said Dr. Pat Horn, Fulcrum’s chief medical officer. “However, in contrast to what was seen in the ReDUX4 study as well as what has been reported in other FSHD studies, the patients receiving placebo in REACH did not show a decline in functional status as measured by RWS and shoulder dynamometry over the 48 weeks of the study. As the largest interventional study ever completed in FSHD, we intend to share the full trial results with patients, study investigators, and the broader FSHD community to ensure others developing treatments for FSHD can benefit from these data.”      

As previously disclosed, Fulcrum had approximately $273.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024. Fulcrum intends to use these resources to advance pociredir for the treatment of SCD, novel therapeutic agents for the treatment of Diamond-Blackfan Anemia (DBA), and early discovery programs.

About the REACH Trial
REACH (NCT05397470) is a Phase 3 multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. The trial enrolled 260 patients who were randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo over a 48-week treatment period. The primary endpoint was the absolute change from baseline in Reachable Workspace (RWS). Secondary endpoint measurements included Muscle Fat Infiltration (MFI) as measured by MRI, shoulder abductor strength as measured by hand-held dynamometry, Patient Global Impression of Change (PGIC), and the Neuro QoL Upper Extremity.

About Losmapimod
Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Although losmapimod had never previously been explored in muscular dystrophies, it had been evaluated in more than 3,600 subjects in clinical trials across multiple other indications with no safety signals attributed to losmapimod. Losmapimod has been granted U.S. Food and Drug Administration (FDA) Fast Track designation and Orphan Drug Designation for the treatment of FSHD.

About FSHD
FSHD is a serious, rare, progressive and debilitating disease for which there are no approved treatments. It is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving primarily the face, scapula and shoulders, upper arms, and abdomen. Impact on patients includes relentless and accumulating muscle and functional loss impacting their ability to perform activities of daily living, loss of upper limb function, loss of mobility and independence, and chronic pain. FSHD is one of the most common forms of muscular dystrophy and has an estimated patient population of 30,000 in the United States alone.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including express or implied statements regarding suspending losmapimod development and the future of the program; completing a full evaluation of the REACH data and sharing the same; intended use of cash and cash equivalents and marketable securities; further advancement of pociredir and Fulcrum’s earlier stage program for DBA and other discovery programs; among others. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with continued development of losmapimod; resuming development of losmapimod following an unsuccessful Phase 3 trial; sufficiency of Fulcrum’s cash resources; ; Fulcrum’s ability to advance any earlier stage product candidates in or into clinical trials; initiating and enrolling clinical trials on the timeline expected or at all; replicating in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials; obtaining, maintaining or protecting intellectual property rights related to any product candidates; obtaining and maintaining necessary approvals from the FDA and other regulatory authorities;;  managing expenses; managing executive and employee turnover; and raising the substantial additional capital needed to achieve its business objectives, among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Fulcrum’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in Fulcrum’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Fulcrum’s views as of the date hereof and should not be relied upon as representing Fulcrum’s views as of any date subsequent to the date hereof. Fulcrum anticipates that subsequent events and developments will cause Fulcrum’s views to change. However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

Contact:

Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

FAQ

What were the results of Fulcrum Therapeutics' Phase 3 REACH trial for losmapimod in FSHD?

The Phase 3 REACH trial failed to meet its primary endpoint. Losmapimod did not show significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to achieve statistical significance.

How did the REACH trial results impact Fulcrum Therapeutics' stock (FULC)?

The negative trial results led Fulcrum Therapeutics (FULC) to announce plans to suspend the losmapimod program in FSHD. This news likely had a negative impact on the stock, although specific stock price movements were not mentioned in the press release.

What is Fulcrum Therapeutics' financial position after the REACH trial results?

As of June 30, 2024, Fulcrum Therapeutics had approximately $273.8 million in cash, cash equivalents, and marketable securities. This robust cash position enables the company to continue developing therapies for other diseases with high unmet needs.

What are Fulcrum Therapeutics' plans following the suspension of the losmapimod program?

Fulcrum Therapeutics plans to redirect its resources to advance pociredir for the treatment of sickle cell disease (SCD), develop novel therapeutic agents for Diamond-Blackfan Anemia (DBA), and pursue early discovery programs.